SCHEMBL20596644

SCHEMBL20596644

CCOC(=O)Cc1cn2c(Br)ccc(N)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.41
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
ALDH1A1 P00352 5/20 0.41
TDP1 Q9NUW8 4/20 0.41
MAPT P10636 4/20 0.41
THRB P10828 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
CHEK1 O14757 1/20 0.39
FPR1 P21462 3/20 0.39
POLB P06746 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
LMNA P02545 3/20 0.38
HPGD P15428 2/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596642 0.80 SMN1; SMN2 (0.41) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL20596641 0.79 SMN1; SMN2 (0.38) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL20595976 0.79 ALDH1A1 (0.39) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL20596634 0.78 LMNA (0.40) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL20596633 0.77 GAA (0.47) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL7982689 0.76 ALDH1A1 (0.46) KDM4EMEN1KMT2AALDH1A1TDP1
Hydrochloric Acid SCHEMBL23391613 0.76 GAA (0.46) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL20596629 0.72 ALDH1A1 (0.47) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL20595928 0.72 KDM4E (0.43) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL7982683 0.72 GAA (0.47) KDM4EMEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 KDM4E 1618/4885MEN1 1598/4885KMT2A 1475/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR KDM4E 1423/4885MEN1 2393/4885KMT2A 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.